1 / 10

DOT Drug & Alcohol Testing Regulatory Update

DOT Drug & Alcohol Testing Regulatory Update. Dr. Donna Smith FirstLab, Inc. dsmith@firstlab.com. Part 40 Amendments. Final Rule June 08; effective 08-25-08 Specimen validity testing mandatory Direct observation procedures for specimen collection modified

urvi
Download Presentation

DOT Drug & Alcohol Testing Regulatory Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DOT Drug & Alcohol Testing Regulatory Update Dr. Donna Smith FirstLab, Inc. dsmith@firstlab.com

  2. Part 40 Amendments • Final Rule June 08; effective 08-25-08 • Specimen validity testing mandatory • Direct observation procedures for specimen collection modified • Changes for MRO interpretation and reporting of multiple invalid specimen results; multiple specimens collected at one testing event; multiple results on a specimen

  3. Specimen Validity Testing (SVT) • Mandatory for all DOT drug testing • Minimum SVT requirements for laboratory • Creatinine (if less than 20 must also measure Specific Gravity) • pH • One or more oxidizing agents • Criteria for adulterated, substituted and invalid remain the same

  4. Invalid Specimens • DOT has adopted the DHHS guidance to laboratories for what they report as “invalid Specimen” • 12 circumstances that require laboratory to report a specimen as invalid • MRO has responsibility for discussing an invalid result with the certifying scientist before interviewing the donor • Purpose of this discussion is to determine if additional testing of the specimen at another laboratory is beneficial

  5. Invalid Specimen • Donor interview is to determine if there is a medical explanation for the circumstances that rendered the specimen invalid • If there is no medical explanation, the test is cancelled and an immediate re-collection under direct observation procedures is required • If there is a medical explanation for the invalid specimen (e.g. medication interference), the test is cancelled and there is no recollection of a specimen • If donor admits to drug use, the MRO must write and sign a statement documenting the donor’s admission and report same to DER • Test is cancelled • If donor admits to attempting adulteration, the MRO will report the result as a refusal to test

  6. Direct Observation Collections • Required in the following circumstances: • Donor presents a specimen with temperature out of range • Donor presents a specimen that collector believes was adulterated or substituted • MRO cancels a test and requires a re-collection of a specimen because- • Specimen creatinine was 2-5 mg/dL • Specimen was invalid and there was no medical explanation • Split specimen was requested and was not available for reconfirmation • Direct observation procedure provides for more visual scrutiny by observer/collector • Donor must position clothing so that the observer can view the donor’s body from chest to knees (front & back)—to check for a urine substitution or adulteration devise. • After inspection, the donor may reposition clothing and provide specimen with observer directly observing the urine leaving the body into the collection container

  7. Multiple Results on a Specimen • If specimen is both positive and adulterated or substituted, MRO reports both positive and refusal to test determinations for the test • If specimen is verified as positive and/or refusal to test and is also invalid, MRO does not cancel test or report specimen invalidity • Positive dilute is reported to DER, however no re-collection is authorized

  8. FMCSA 49 CFR Part 382 • No changes to Part 382 in past 2 years • Random testing rates for Drug and Alcohol testing for 2009 remain the same (50%-drug, 10%-alcohol) • Random testing • Must do random selections at least 4 times per year • Must test all selected drivers during the selection period (quarter, month, etc.) • Can only use “alternate selection(s)” if selected drivers are unavailable for the entire selection period (e.g. terminated, laid-off, long term disability, etc.) • Cannot give prior notice for random testing—must be tested immediately after being notified

  9. FMCSA 49 CFR Part 382 • Reminders for Part 382 compliance • Make sure policy is current • Negative dilutes • Invalid/cancelled tests • Refusal to test definitions • Supervisory training documentation for all supervisors of CDL drivers • Drug and Alcohol awareness information provided to all new-hire CDL employees • Ensure random testing percentage is attained for calendar year • Ensure random pool is updated at least quarterly • Prior D & A violation check on all employees hired or transferred into a CDL position

  10. Program Resources from DOT • Best Practices for DOT Random Drug and Alcohol Testing • Employer Guide to DOT Testing • Employee Booklet (What Employees Need To Know About DOT Drug & Alcohol Testing) • DOT Specimen Collection Guidelines All of the above are available at www.dot.gov/ost/dapc

More Related